U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H28O2
Molecular Weight 348.4779
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BEXAROTENE

SMILES

CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(O)=O)C(C)(C)CCC2(C)C

InChI

InChIKey=NAVMQTYZDKMPEU-UHFFFAOYSA-N
InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)

HIDE SMILES / InChI

Molecular Formula C24H28O2
Molecular Weight 348.4779
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15056048

Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. Bexarotene is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors have biologic activity distinct from that of retinoic acid receptors (RARs). Bexarotene selectively binds and activates retinoid X receptor subtypes (RXRa, RXRb, RXRg). RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs), vitamin D receptor, thyroid receptor, and peroxisome proliferator activator receptors (PPARs). Once activated, these receptors function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression in vivo in some animal models. The exact mechanism of action of bexarotene in the treatment of cutaneous T-cell lymphoma (CTCL) is unknown.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TARGRETIN

Approved Use

TARGRETIN® (bexarotene) Capsules are indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. TARGRETIN (bexarotene) is a retinoid indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. (1)

Launch Date

9.4642563E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
652.44 ng/mL
300 mg/m² 1 times / day multiple, oral
dose: 300 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BEXAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2133.34 ng × h/mL
300 mg/m² 1 times / day multiple, oral
dose: 300 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BEXAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.18 h
300 mg/m² 1 times / day multiple, oral
dose: 300 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BEXAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
500 mg/m2 1 times / day multiple, oral
Studied dose
Dose: 500 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 500 mg/m2, 1 times / day
Sources: Page: p.1003
unhealthy, 56
n = 45
Health Status: unhealthy
Condition: Breast Cancer
Age Group: 56
Sex: F
Population Size: 45
Sources: Page: p.1003
Disc. AE: Granulocytopenia...
AEs leading to
discontinuation/dose reduction:
Granulocytopenia (severe, 2.2%)
Sources: Page: p.1003
500 mg/m2 1 times / day multiple, oral
Studied dose
Dose: 500 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 500 mg/m2, 1 times / day
Sources: Page: p.1004
unhealthy, 56
n = 45
Health Status: unhealthy
Condition: Breast Cancer
Age Group: 56
Sex: F
Population Size: 45
Sources: Page: p.1004
Disc. AE: Erythema, Triglyceride increased...
AEs leading to
discontinuation/dose reduction:
Erythema (grade 2, 2.2%)
Triglyceride increased (grade 2, 2.2%)
Sources: Page: p.1004
400 mg/m2 1 times / day multiple, oral
MTD
Dose: 400 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg/m2, 1 times / day
Co-administed with::
Vinorelbine, i.v(15-30 mg/m2; once in 2 weeks)
cisplatin, i.v(100 mg/m2; once in 6 weeks)
Sources: Page: p.2629, 2632
unhealthy, 59
n = 28
Health Status: unhealthy
Condition: Non-small-cell lung cancer
Age Group: 59
Sex: M+F
Population Size: 28
Sources: Page: p.2629, 2632
DLT: Pancreatitis...
Dose limiting toxicities:
Pancreatitis (grade 2, 3.57%)
Sources: Page: p.2629, 2632
1000 mg/m2 1 times / day multiple, oral
Highest studied dose
Dose: 1000 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg/m2, 1 times / day
Sources: Page: p.1660
unhealthy
n = 6
Health Status: unhealthy
Condition: Cancer
Sex: M+F
Population Size: 6
Sources: Page: p.1660
DLT: Transaminitis, Hyperbilirubinemia...
Dose limiting toxicities:
Transaminitis (grade 3, 16.7%)
Hyperbilirubinemia (grade 3, 16.7%)
Sources: Page: p.1660
300 mg/m2 1 times / day multiple, oral
Recommended
Dose: 300 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Cutaneous T-cell lymphoma
Sources: Page: p.1
Disc. AE: Birth defects, Hyperlipidemia...
AEs leading to
discontinuation/dose reduction:
Birth defects
Hyperlipidemia
Pancreatitis
Hepatotoxicity
Cholestasis
Hepatic failure
Hypothyroidism
Neutropenia
Photosensitivity
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Granulocytopenia severe, 2.2%
Disc. AE
500 mg/m2 1 times / day multiple, oral
Studied dose
Dose: 500 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 500 mg/m2, 1 times / day
Sources: Page: p.1003
unhealthy, 56
n = 45
Health Status: unhealthy
Condition: Breast Cancer
Age Group: 56
Sex: F
Population Size: 45
Sources: Page: p.1003
Erythema grade 2, 2.2%
Disc. AE
500 mg/m2 1 times / day multiple, oral
Studied dose
Dose: 500 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 500 mg/m2, 1 times / day
Sources: Page: p.1004
unhealthy, 56
n = 45
Health Status: unhealthy
Condition: Breast Cancer
Age Group: 56
Sex: F
Population Size: 45
Sources: Page: p.1004
Triglyceride increased grade 2, 2.2%
Disc. AE
500 mg/m2 1 times / day multiple, oral
Studied dose
Dose: 500 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 500 mg/m2, 1 times / day
Sources: Page: p.1004
unhealthy, 56
n = 45
Health Status: unhealthy
Condition: Breast Cancer
Age Group: 56
Sex: F
Population Size: 45
Sources: Page: p.1004
Pancreatitis grade 2, 3.57%
DLT, Disc. AE
400 mg/m2 1 times / day multiple, oral
MTD
Dose: 400 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg/m2, 1 times / day
Co-administed with::
Vinorelbine, i.v(15-30 mg/m2; once in 2 weeks)
cisplatin, i.v(100 mg/m2; once in 6 weeks)
Sources: Page: p.2629, 2632
unhealthy, 59
n = 28
Health Status: unhealthy
Condition: Non-small-cell lung cancer
Age Group: 59
Sex: M+F
Population Size: 28
Sources: Page: p.2629, 2632
Hyperbilirubinemia grade 3, 16.7%
DLT
1000 mg/m2 1 times / day multiple, oral
Highest studied dose
Dose: 1000 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg/m2, 1 times / day
Sources: Page: p.1660
unhealthy
n = 6
Health Status: unhealthy
Condition: Cancer
Sex: M+F
Population Size: 6
Sources: Page: p.1660
Transaminitis grade 3, 16.7%
DLT
1000 mg/m2 1 times / day multiple, oral
Highest studied dose
Dose: 1000 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg/m2, 1 times / day
Sources: Page: p.1660
unhealthy
n = 6
Health Status: unhealthy
Condition: Cancer
Sex: M+F
Population Size: 6
Sources: Page: p.1660
Birth defects Disc. AE
300 mg/m2 1 times / day multiple, oral
Recommended
Dose: 300 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Cutaneous T-cell lymphoma
Sources: Page: p.1
Cholestasis Disc. AE
300 mg/m2 1 times / day multiple, oral
Recommended
Dose: 300 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Cutaneous T-cell lymphoma
Sources: Page: p.1
Hepatic failure Disc. AE
300 mg/m2 1 times / day multiple, oral
Recommended
Dose: 300 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Cutaneous T-cell lymphoma
Sources: Page: p.1
Hepatotoxicity Disc. AE
300 mg/m2 1 times / day multiple, oral
Recommended
Dose: 300 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Cutaneous T-cell lymphoma
Sources: Page: p.1
Hyperlipidemia Disc. AE
300 mg/m2 1 times / day multiple, oral
Recommended
Dose: 300 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Cutaneous T-cell lymphoma
Sources: Page: p.1
Hypothyroidism Disc. AE
300 mg/m2 1 times / day multiple, oral
Recommended
Dose: 300 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Cutaneous T-cell lymphoma
Sources: Page: p.1
Neutropenia Disc. AE
300 mg/m2 1 times / day multiple, oral
Recommended
Dose: 300 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Cutaneous T-cell lymphoma
Sources: Page: p.1
Pancreatitis Disc. AE
300 mg/m2 1 times / day multiple, oral
Recommended
Dose: 300 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Cutaneous T-cell lymphoma
Sources: Page: p.1
Photosensitivity Disc. AE
300 mg/m2 1 times / day multiple, oral
Recommended
Dose: 300 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/m2, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Cutaneous T-cell lymphoma
Sources: Page: p.1
PubMed

PubMed

TitleDatePubMed
Therapeutic advances in biological response modifiers in the treatment of cutaneous T-cell lymphoma.
2001
Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines.
2001 Aug 1
Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer.
2001 Feb
Bexarotene metabolism in rat, dog, and human, synthesis of oxidative metabolites, and in vitro activity at retinoid receptors.
2001 Jul
Therapy options in cutaneous T-cell lymphoma.
2001 Oct
Cutaneous T-cell lymphoma. New immunomodulators.
2001 Oct
Where to next with retinoids for cancer therapy?
2001 Oct
Oral bexarotene in the treatment of cutaneous T-cell lymphoma.
2001 Sep
A review of cancer chemopreventive agents.
2001 Sep
Retinoids--which dermatological indications will benefit in the near future?
2001 Sep-Oct
Retinoid signalling and gene expression in neuroblastoma cells: RXR agonist and antagonist effects on CRABP-II and RARbeta expression.
2002
Risk management strategies in the Physicians' Desk Reference product labels for pregnancy category X drugs.
2002
Treatment of cutaneous T cell lymphoma: 2001.
2002
Treatment of cutaneous T cell lymphoma: current status and future directions.
2002
Mechanism of selective retinoid X receptor agonist-induced hypothyroidism in the rat.
2002 Aug
Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox.
2002 Aug 15
Validated liquid chromatographic method for the determination of bexarotene in human plasma.
2002 Aug 5
Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma.
2002 Dec
A pharmacophore for human pregnane X receptor ligands.
2002 Jan
Bexarotene gel: a Food and Drug Administration-approved skin-directed therapy for early-stage cutaneous T-cell lymphoma.
2002 Mar
Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
2002 May
T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities.
2002 May 31
Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
2002 Sep
Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approaches.
2003
Treatment planning in cutaneous T-cell lymphoma.
2003
Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas.
2003 Apr
Therapy of cutaneous lymphoma--current practice and future developments.
2003 Aug
[Standard and experimental therapy of cutaneous T-cell lymphoma].
2003 Dec
Effects of oral bexarotene (targretin) on the minimal erythema dose for broadspectrum UVB light.
2003 Jul-Aug
Gateways to clinical trials.
2003 Jun
Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma.
2003 Jun
Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma.
2003 Mar
Long-term control of mycosis fungoides of the hands with topical bexarotene.
2003 Mar
Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial.
2003 Nov
Current status of cutaneous T-cell lymphoma: molecular diagnosis, pathogenesis, therapy and future directions.
2003 Oct
Experiences with monolithic LC phases in quantitative bioanalysis.
2003 Oct 15
Responsiveness to the retinoic acid receptor-selective retinoid LGD1550 correlates with abrogation of transforming growth factor alpha/epidermal growth factor receptor autocrine signaling in head and neck squamous carcinoma cells.
2003 Sep 15
A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands.
2004
Combination of bexarotene and psoralen-UVA therapy in a patient with Mycosis fungoides.
2004
The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells.
2004 Aug
Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma.
2004 Jul
Bexarotene: new preparation. Cutaneous lymphoma: too many adverse effects.
2004 Jun
How retinoids regulate breast cancer cell proliferation and apoptosis.
2004 Jun
Therapy for mycosis fungoides.
2004 Jun
Potentiation of the teratogenic effects induced by coadministration of retinoic acid or phytanic acid/phytol with synthetic retinoid receptor ligands.
2004 Nov
Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.
2004 Oct
Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
2004 Sep
Patents

Patents

Sample Use Guides

The recommended initial dose of Targretin (bexarotene) capsules is 300 mg/m2 /day. Capsules should be taken as a single oral daily dose with a meal.
Route of Administration: Oral
Bexarotene (10−6 mol/L) inhibits the transactivation potential of NF-κB in an RXR-dependent manner through decreased promoter permissiveness without interfering with NF-κB nuclear translocation and binding to its responsive elements. Inhibition of transcription results from the release of 300 coactivator from NF-κB target gene promoters and subsequent histone deacetylation.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:04:12 UTC 2023
Edited
by admin
on Wed Jul 05 23:04:12 UTC 2023
Record UNII
A61RXM4375
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BEXAROTENE
EMA EPAR   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
BEXAROTENE [EMA EPAR]
Common Name English
Bexarotene [WHO-DD]
Common Name English
BEXAROTENE [MART.]
Common Name English
BEXAROTENE [VANDF]
Common Name English
BEXAROTENE [ORANGE BOOK]
Common Name English
LGD-1069
Code English
LGD1069
Code English
bexarotene [INN]
Common Name English
P-(1-(5,6,7,8-TETRAHYDRO-3,5,5,8,8-PENTAMETHYL-2-NAPHTHYL)VINYL)BENZOIC ACID
Common Name English
BEXAROTENE [USAN]
Common Name English
LG-100069
Code English
LG100069
Code English
TARGRETIN
Brand Name English
4-(1-(5,6,7,8-TETRAHYDRO-3,5,5,8,8-PENTAMETHYL-2-NAPHTHALENYL)ETHENYL)BENZOIC ACID
Systematic Name English
BEXAROTENE [HSDB]
Common Name English
BEXAROTENE [MI]
Common Name English
BEXAROTENE [JAN]
Common Name English
NSC-747528
Code English
Classification Tree Code System Code
NDF-RT N0000007700
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
LIVERTOX NBK548336
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
WHO-VATC QL01XX25
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
NDF-RT N0000007700
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
NDF-RT N0000175607
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
NDF-RT N0000007700
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
WHO-ATC L01XX25
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
NCI_THESAURUS C804
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
NDF-RT N0000007700
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
EMA ASSESSMENT REPORTS TARGRETIN (AUTHORIZED: LYMPHOMA, T-CELL, CUTANEOUS)
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
FDA ORPHAN DRUG 124699
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
NDF-RT N0000007700
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
Code System Code Type Description
CAS
153559-49-0
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
PRIMARY
EPA CompTox
DTXSID1040619
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
PRIMARY
NSC
747528
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
PRIMARY
MERCK INDEX
M2468
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
PRIMARY Merck Index
SMS_ID
100000089393
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
PRIMARY
DRUG BANK
DB00307
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
PRIMARY
INN
7782
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
PRIMARY
CHEBI
50859
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
PRIMARY
USAN
KK-21
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
PRIMARY
FDA UNII
A61RXM4375
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
PRIMARY
EVMPD
SUB00795MIG
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
PRIMARY
IUPHAR
2807
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
PRIMARY
NCI_THESAURUS
C1635
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
PRIMARY
WIKIPEDIA
BEXAROTENE
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
PRIMARY
HSDB
7453
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
PRIMARY
DRUG CENTRAL
361
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
PRIMARY
MESH
C095105
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
PRIMARY
PUBCHEM
82146
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
PRIMARY
DAILYMED
A61RXM4375
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
PRIMARY
RXCUI
233272
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
PRIMARY RxNorm
ChEMBL
CHEMBL1023
Created by admin on Wed Jul 05 23:04:12 UTC 2023 , Edited by admin on Wed Jul 05 23:04:12 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
TARGET -> AGONIST
TARGET -> AGONIST
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
MAJOR
Related Record Type Details
METABOLITE -> PARENT
MAJOR
PLASMA
METABOLITE -> PARENT
PLASMA
METABOLITE -> PARENT
PLASMA
METABOLITE -> PARENT
PLASMA
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION